The combination of gene expression profiling, proteomics and bioinformatical approaches as applied to these cell lines are necessary to better understand potential pathways through which MT1 expression and cell motility are regulated, and are likely to reveal new therapeutic targets for ovarian cancer. Here, MT1F is linked to ovarian carcinoma.